Cashu
Congress reauthorizes Rare Pediatric Disease PRV program, preserving Atossa Therapeutics' DMD voucher eligibility
27 days ago
Stocks
Health Care
atos
Atossa Therapeutics
NASDAQ: ATOS
-0.15 (-3.21%)
4.53
USD
At close at Mar 06, 21:38 UTC
Latest Atossa Therapeutics News
prnewswire.com
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
30 days ago
prnewswire.com
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
about 2 months ago
prnewswire.com
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
about 2 months ago
prnewswire.com
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
3 months ago
prnewswire.com
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
3 months ago
prnewswire.com
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
3 months ago
prnewswire.com
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
4 months ago
prnewswire.com
Atossa Therapeutics to Present at the Maxim Growth Summit 2025
5 months ago
prnewswire.com
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
5 months ago
prnewswire.com
Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
5 months ago
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.